No FDA approved drug targeting PPARδ is available so far notwithstanding early-stage clinical trials on the use of PPARδ agonists (e.g., KD-3010 and MBX-8025) to treat atherosclerosis, metabolic disorders and liver injury [4–6]. Here, PPARD is linked to metabolic disease.